These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16787708)

  • 1. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
    Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
    Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
    Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
    J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
    Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
    J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease.
    Lin JJ; Yueh KC; Liu CS; Liu JT; Lin SZ
    Acta Neurol Taiwan; 2007 Sep; 16(3):150-7. PubMed ID: 17966954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
    Camicioli RM; Bouchard TP; Somerville MJ
    Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
    Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of homocysteine, vitamin B12, folic acid, and MTHFR C677T in patients with a thrombotic event or recurrent fetal loss.
    Nadir Y; Hoffman R; Brenner B
    Ann Hematol; 2007 Jan; 86(1):35-40. PubMed ID: 17043779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial function markers in parkinsonian patients with hyperhomocysteinemia.
    Bostantjopoulou S; Katsarou Z; Frangia T; Hatzizisi O; Papazisis K; Kyriazis G; Kiosseoglou G; Kazis A
    J Clin Neurosci; 2005 Aug; 12(6):669-72. PubMed ID: 16040247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy.
    Vurucu S; Demirkaya E; Kul M; Unay B; Gul D; Akin R; Gokçay E
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):844-8. PubMed ID: 18234410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.
    Caccamo D; Gorgone G; Currò M; Parisi G; Di Iorio W; Menichetti C; Belcastro V; Parnetti L; Rossi A; Pisani F; Ientile R; Calabresi P
    Neuromolecular Med; 2007; 9(3):249-54. PubMed ID: 17914182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
    Brattström L
    Neurology; 2001 Jan; 56(2):281; author reply 281-2. PubMed ID: 11160979
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
    Kuhn W; Hummel T; Woitalla D; Müller T
    Neurology; 2001 Jan; 56(2):281; author reply 281-2. PubMed ID: 11271164
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
    Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
    Gorgone G; Currò M; Ferlazzo N; Parisi G; Parnetti L; Belcastro V; Tambasco N; Rossi A; Pisani F; Calabresi P; Ientile R; Caccamo D
    Neuromolecular Med; 2012 Mar; 14(1):84-90. PubMed ID: 22354693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism C776G in the transcobalamin II gene and homocysteine, folate and vitamin B12 concentrations. Association with MTHFR C677T and A1298C and MTRR A66G polymorphisms in healthy children.
    Aléssio AC; Höehr NF; Siqueira LH; Bydlowski SP; Annichino-Bizzacchi JM
    Thromb Res; 2007; 119(5):571-7. PubMed ID: 16820193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Homocysteine and cognitive impairment in Parkinson's disease].
    Martín-Fernández JJ; Carles-Díes R; Cañizares F; Parra S; Avilés F; Villegas I; Morsi-Hassan O; Fernández-Barreiro A; Herrero MT
    Rev Neurol; 2010 Feb 1-15; 50(3):145-51. PubMed ID: 20146187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G1793A polymorphisms in the methylene-tetrahydrofolate gene: effect of folic acid on homocysteine levels.
    Melo SS; Persuhn DC; Meirelles MS; Jordao AA; Vannucchi H
    Mol Nutr Food Res; 2006 Aug; 50(8):769-74. PubMed ID: 16865747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients.
    Mtiraoui N; Ezzidi I; Chaieb M; Marmouche H; Aouni Z; Chaieb A; Mahjoub T; Vaxillaire M; Almawi WY
    Diabetes Res Clin Pract; 2007 Jan; 75(1):99-106. PubMed ID: 16828193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.